Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?

International Journal of Cardiology

Volumn 219, Issue , 2016, Pages 111-114

  Lippi, Giuseppe ^a   Sanchis Gomar, Fabian ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b Research Institute Hospital 12 de Octubre ^*  (Spain)

Author keywords

B type natriuretic peptide; BNP; Heart failure; Neprilysin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; PLACEBO; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TETRAZOLE DERIVATIVE;

CARDIOVASCULAR RISK; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HOSPITALIZATION; HUMAN; PATIENT MONITORING; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG MONITORING; FEMALE; MALE; TRENDS;

AMINOBUTYRATES; ANIMALS; DRUG MONITORING; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDE FRAGMENTS; TETRAZOLES;

EID: 84974831035     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.019     Document Type: Review

References (24)

1. M.R. Wilkins, J. Redondo, and L.A. Brown The natriuretic-peptide family Lancet 349 1997 1307 1310
2. T. Sudoh, K. Kangawa, N. Minamino, and H. Matsuo A new natriuretic peptide in porcine brain Nature 332 1988 78 81
3. Y. Ogawa, H. Itoh, N. Tamura, S. Suga, T. Yoshimasa, M. Uehira, S. Matsuda, S. Shiono, H. Nishimoto, and K. Nakao Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene J. Clin. Invest. 93 1994 1911 1921
4. B.H. Wang, T.G. von Lueder, A.R. Kompa, L. Huang, R. Webb, P. Jordaan, D. Atar, and H. Krum Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis Int. J. Cardiol. 186 2015 104 105
5. L. King, and M.R. Wilkins Natriuretic peptide receptors and the heart Heart 87 2002 314 315
6. F. Bodey, I. Hopper, and H. Krum Neprilysin inhibitors preserve renal function in heart failure Int. J. Cardiol. 179 2015 329 330
7. L.R. Potter, A.R. Yoder, D.R. Flora, L.K. Antos, and D.M. Dickey Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications Handb. Exp. Pharmacol. 191 2009 341 366
8. C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.H. Drazner, G.C. Fonarow, S.A. Geraci, T. Horwich, J.L. Januzzi, M.R. Johnson, E.K. Kasper, W.C. Levy, F.A. Masoudi, P.E. McBride, J.J. McMurray, J.E. Mitchell, P.N. Peterson, B. Riegel, F. Sam, L.W. Stevenson, W.H. Tang, E.J. Tsai, B.L. Wilkoff, American College of Cardiology Foundation, and American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol. 62 2013 e147 e239
9. S.A. Hill, R.A. Booth, P.L. Santaguida, A. Don-Wauchope, J.A. Brown, M. Oremus, U. Ali, A. Bustamam, N. Sohel, R. McKelvie, C. Balion, and P. Raina Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence Heart Fail. Rev. 19 2014 421 438
10. M. Oremus, R. McKelvie, A. Don-Wauchope, P.L. Santaguida, U. Ali, C. Balion, S. Hill, R. Booth, J.A. Brown, A. Bustamam, N. Sohel, and P. Raina A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods Heart Fail. Rev. 19 2014 413 419
11. A. Vichiendilokkul, A. Tran, and E. Racine Nesiritide: a novel approach for acute heart failure Ann. Pharmacother. 37 2003 247 258
12. C.M. O'Connor, R.C. Starling, A.F. Hernandez, P.W. Armstrong, K. Dickstein, V. Hasselblad, G.M. Heizer, M. Komajda, B.M. Massie, J.J. McMurray, M.S. Nieminen, C.J. Reist, J.L. Rouleau, K. Swedberg, K.F. Adams Jr., S.D. Anker, D. Atar, A. Battler, R. Botero, N.R. Bohidar, J. Butler, N. Clausell, R. Corbalán, M.R. Costanzo, U. Dahlstrom, L.I. Deckelbaum, R. Diaz, M.E. Dunlap, J.A. Ezekowitz, D. Feldman, G.M. Felker, G.C. Fonarow, D. Gennevois, S.S. Gottlieb, J.A. Hill, J.E. Hollander, J.G. Howlett, M.P. Hudson, R.D. Kociol, H. Krum, A. Laucevicius, W.C. Levy, G.F. Méndez, M. Metra, S. Mittal, B.H. Oh, N.L. Pereira, P. Ponikowski, W.H. Tang, S. Tanomsup, J.R. Teerlink, F. Triposkiadis, R.W. Troughton, A.A. Voors, D.J. Whellan, F. Zannad, and R.M. Califf Effect of nesiritide in patients with acute decompensated heart failure N. Engl. J. Med. 365 2011 32 43
13. J.J. McMurray, M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, J.L. Rouleau, V.C. Shi, S.D. Solomon, K. Swedberg, M.R. Zile, and PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure N. Engl. J. Med. 371 2014 993 1004
14. M. Packer, J.J. McMurray, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, J.L. Rouleau, V.C. Shi, S.D. Solomon, K. Swedberg, M. Zile, K. Andersen, J.L. Arango, J.M. Arnold, J. Bělohlávek, M. Böhm, S. Boytsov, L.J. Burgess, W. Cabrera, C. Calvo, C.H. Chen, A. Dukat, Y.C. Duarte, A. Erglis, M. Fu, E. Gomez, A. Gonzàlez-Medina, A.A. Hagège, J. Huang, T. Katova, S. Kiatchoosakun, K.S. Kim, Ö. Kozan, E.B. Llamas, F. Martinez, B. Merkely, I. Mendoza, A. Mosterd, M. Negrusz-Kawecka, K. Peuhkurinen, F.J. Ramires, J. Refsgaard, A. Rosenthal, M. Senni, A.S. Sibulo Jr., J. Silva-Cardoso, I.B. Squire, R.C. Starling, J.R. Teerlink, J. Vanhaecke, D. Vinereanu, R.C. Wong, and PARADIGM-HF Investigators and Coordinators Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 2015 54 61
15. J.A. Norman, D. Little, M. Bolgar, and G. Di Donato Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry Biochem. Biophys. Res. Commun. 175 1991 22 30
16. Z. Abassi, T. Karram, S. Ellaham, J. Winaver, and A. Hoffman Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance Pharmacol. Ther. 102 2004 223 241
17. A.G. Semenov, and A.G. Katrukha Different susceptibility of B-type natriuretic peptide (BNP) and BNP precursor (proBNP) to cleavage by neprilysin: the N-terminal part does matter Clin. Chem. 62 2016 617 622
18. H.K. Gaggin, and J.L. Januzzi Cardiac biomarkers and heart failure Available at: http://www.acc.org/latest-in-cardiology/articles/2015/02/09/13/00/cardiac-biomarkers-and-heart-failure (Last Access 5 May 2016)
19. F. Liang, J. O'Rear, U. Schellenberger, L. Tai, M. Lasecki, G.F. Schreiner, F.S. Apple, A.S. Maisel, N.S. Pollitt, and A.A. Protter Evidence for functional heterogeneity of circulating B-type natriuretic peptide J. Am. Coll. Cardiol. 49 2007 1071 1078
20. N. Vodovar, M.F. Séronde, S. Laribi, E. Gayat, J. Lassus, J.L. Januzzi Jr., R. Boukef, S. Nouira, P. Manivet, J.L. Samuel, D. Logeart, A. Cohen-Solal, A.M. Richards, J.M. Launay, A. Mebazaa, and GREAT Network Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure JACC Heart Fail. 3 2015 629 636
21. O. Vardeny, R. Miller, and S.D. Solomon Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure JACC Heart Fail. 2 2014 663 670
22. V. Mollace, M. Gliozzi, A. Capuano, and F. Rossi Modulation of RAAS-natriuretic peptides in the treatment of HF: old guys and newcomers Int. J. Cardiol. Mar 24 2016 10.1016/j.ijcard.2016.03.085 (Epub ahead of print)
23. P. Rossignol, F. Zannad, and B. Pitt Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries Int. J. Cardiol. 177 2014 731 733
24. A. Clerico, M. Fontana, L. Zyw, C. Passino, and M. Emdin Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review Clin. Chem. 53 2007 813 822